首页> 外文OA文献 >A novel orally administered trimebutine compound (GIC-1001) is anti-nociceptive and features peripheral opioid agonistic activity and Hydrogen Sulphide-releasing capacity in mice

【2h】

A novel orally administered trimebutine compound (GIC-1001) is anti-nociceptive and features peripheral opioid agonistic activity and Hydrogen Sulphide-releasing capacity in mice

机译：一种新的口服施用的三合杂丁化合物（GIC-1001）是抗伤害性的，并具有小鼠外周阿片类毒性活性和硫化氢释放能力

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
N. Cenac; M. Castro; C. Desormeaux; P. Colin; M. Sie; M. Ranger; N. Vergnolle;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. A novel orally administered trimebutine compound (GIC-1001) is anti-nociceptive and features peripheral opioid agonistic activity and Hydrogen Sulphide-releasing capacity in mice [J] . Cenac N., Castro M., Desormeaux C., European journal of pain : . 2016,第5期

机译：新型口服曲美布汀化合物（GIC-1001）具有抗伤害感受性，并具有小鼠外周阿片样物质激动活性和硫化氢释放能力
2. NALOXEGOL: THE FIRST ORALLY ADMINISTERED, PERIPHERALLY ACTING, mu OPIOID RECEPTOR ANTAGONIST, APPROVED FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION [J] . Corsetti M., Tack J. Drugs of today: Medicamentos de actualidad . 2015,第8期

机译：纳洛索尔：首次口服，阿片类药物治疗，μ阿片类受体拮抗剂，被批准用于治疗阿片类药物引起的便秘
3. Orally administered delta opioid agonist peptide rubiscolin-6 stimulates food intake in aged mice with ghrelin resistance [J] . Miyazaki Yuri, Kaneko Kentaro, Iguchi Shin, Molecular Nutrition and Food Research . 2014,第10期

机译：口服给予δ阿片样物质激动剂rubiscolin-6刺激生长激素缺乏症抵抗力的衰老小鼠的食物摄入
4. Macrophage Activity and Capacity Following Oral Administration of Cocoa Extract to Mice [C] . Ariza Budi Tunjung Sari, Teguh Wahyudi, Misnawi, International Seminar on Molecular and Cellular Life Sciences . 2016

机译：口服可可提取物后巨噬细胞活性和能力
5. Orally administered H-Dmt-Tic-Lys-NH-CH2-Ph (MZ-2) a potent μ-/δ-opioid receptor antagonist regulates obese-related factors in mice [O] . Ewa D. Marczak, Yunden Jinsmaa, Page H. Myers, -1

机译：口服施用的H-DMT-TIC-LYS-NH-CH2-pH（MZ-2）有效的μ-/δ-阿片受体拮抗剂调节小鼠中的肥胖相关因子
6. Orally administered H-Dmt-Tic-Lys-NH-CH2-Ph (MZ-2), a potent mu/delta-opioid receptor antagonist, regulates obese-related factors in mice [O] . MARCZAK E.D, JINSMAA Y, MYERS P.H, 2009

机译：口服H-Dmt-Tic-Lys-NH-CH2-Ph（MZ-2），一种有效的mu /δ阿片类受体拮抗剂，可调节小鼠肥胖相关因子

A novel orally administered trimebutine compound (GIC-1001) is anti-nociceptive and features peripheral opioid agonistic activity and Hydrogen Sulphide-releasing capacity in mice

著录项

引文网络

相似文献

相关主题

期刊订阅